Drug Trial Radar · NCT00307502
Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV
Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
675
Actual
Start
Jan 2005
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- Germans Trias i Pujol HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- First posted
- Mar 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the influence of the individual characteristics on the pharmacokinetic parameters in the Spanish population of HIV-infected subjects.
Conditions
- HIV Infections
Interventions
NevirapineDrug
tablets 200 mg, 400 mg/day
EfavirenzDrug
tablets 600 mg, 600 mg/day
Indinavir/ritonavirDrug
Indinavir: capsules 400 mg, 1600 mg/day Ritonavir: capsules 100 mg, 200 mg/day
NelfinavirDrug
tablets 250 mg, 2500 mg/day
Saquinavir/ritonavirDrug
Saquinavir: tablets 500 mg, 2000 mg/day Ritonavir: tablets 100 mg, 200 mg/day
Lopinavir/ritonavirDrug
tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
AtazanavirDrug
capsules 200 mg, 400 mg/day
Atazanavir/ritonavirDrug
Atazanavir: capsules 150 mg, 300 mg/day Ritonavir: capsules 100 mg, 200 mg/day
Fos-amprenavir/ritonavirDrug
Fos-amprenavir: capsules 700 mg, 1400 mg/day Ritonavir: capsules 100 mg, 200 mg/day
Tipranavir/ ritonavirDrug
Tipranavir: tablets 250 mg, 1000 mg/day Ritonavir: capsules 100 mg, 400 mg/day
Darunavir/ritonavirDrug
Darunavir: tablets 300 mg, 1200 mg/day Ritonavir: capsules 100 mg, 200 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint is the plasma concentration of the PI/NNRTI drugs (Ka absorption constant, CI: plasma clearance, Vd: volume of distribution).Time frame: In the 12 hour (h) pharmacokinetic curve
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
Hospital de Figueres
Figueras, Barcelona, Spain
Fundació Hospital-Asil de Granollers
Granollers, Barcelona, Spain
Hospital de Vic
Vic, Barcelona, Spain
Hospital Universitari Sant Joan de Reus
Reus, Tarragona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.